Work

Glycemic control, including Time in Tight Range (TITR) evaluation, in children with type 1 diabetes treated with the MiniMed 780G system: a 3-year prospective, observational, two-center study

Year: 2026

Type: article

Abstract: Background: The MiniMed 780G was the first commercially available automated insulin delivery (AID) system in Poland. The aim of this study was to analyze glycemic management in children with type 1 diabetes (T1D) after three years of using the system. Materials and methods: The data included anthropometric measurements, information from insulin pumps, and continuous glucose monitoring (CGM) from fifty children with T1D (mean age: 9.9 ± 2.4 years; T1D duration at baseline: 3.9 ± 2.56 years) using the MiniMed 780G. The data were collected at AID initiation, 12 and 36 months after starting its use. Results: Coefficient of variation (CV) and body mass index (BMI) z-scores at baseline and after 3 years were comparable (p > 0.05). TITR firstly increased after the AID system implementation with the peak value after 6 months (60.82% ± 9.34), then the values decreased to 56.50%± 10.78% after 3 years (p<0.001). Time in range (70-180 mg/dL) decreased after 3 years of observation compared to peak values at 6 and 12 months (77.74% ± 7.65% versus 81.16% ± 7.83% and 80.40% ± 8.25%, respectively, p<0.005. The percentage of auto-correction in total daily insulin dose increased significantly (11.24% ± 6.08% 2 weeks of AID system usage vs. 16.34% ± 6.69% after 3 years; p < 0.001). Conclusions: Despite a slight deterioration after 3 years, optimal glycemic management was maintained throughout the observation period. GCM metrics remained within recommended values in early adolescence, most likely due to auto-correction boluses.

Source: Frontiers in Endocrinology

DOI: 10.3389/fendo.2026.1750164